Allogeneic hematopoietic cell transplantation (allo-HCT) is inherently associated with a risk of non-relapse mortality (NRM) that varies greatly depending on transplant and patient characteristics. To quantify the risk of NRM, several pretransplant predictive scores have been developed and independently validated, although the predictive capacity of the most widely used models (including the HCT-Comorbidity Index (HCT-CI) 1 and the European Group for Blood and Marrow Transplantation (EBMT) score 2 ) is limited. Recently, the Acute Leukemia Working Party (ALWP) of the EBMT published in Leukemia a new predictive score of NRM by integrating 16 parameters of these two models. 3 These parameters were chosen according to their individual hazard ratio (HR) for NRM in the multivariate analysis in a large and homogeneous population of patients receiving a reduced-intensity conditioning allo-HCT (allo-RIC) for AML in first CR. This new model resulted in a relatively strong predictive tool for 2-year NRM in the same population of patients in which it was developed. However, this study lacked an external and independent validation.
To determine the predictive capacity of the new integrated score and to compare it with the HCT-CI and EBMT score we designed a retrospective study including 232 consecutive patients receiving an allo-RIC in one of the two participating centers from January 2000 to December 2011. The transplant protocol was approved by the local and national ethics committees and the patients gave written informed consent for their inclusion. The transplant protocol has been published elsewhere in detail. 4 In brief, conditioning regimen for all patients included fludarabine (150 mg/m 2 ) in combination with melphalan (70-140 mg/m 2 ), busulfan (8-10 mg/kg), cyclophosphamide (120 mg/kg) or low-dose TBI (2 Gy). GvHD prophylaxis included a calcineurin inhibitor (mainly cyclosporine A) in combination with short-course methotrexate, mycophenolate mofetil or sirolimus. Acyclovir, trimethoprim-sulfamethoxazole, fluconazole and quinolones (ciprofloxacin or norfloxacin) were administered as infectious prophylaxis. CMV infection screening for guiding pre-emptive therapy was performed as described. 5 Galactomannan Platelia assay (Bio-Rad Laboratories, Hercules, CA, USA) was routinely performed since 2003. 6 Cord blood and haploidentical transplants were not included in this study. In vivo T-cell depletion was used in patients receiving a transplant from HLA-mismatched donors.
The HCT-CI and the EBMT score were calculated by a single investigator (P.B.) as originally defined 1,2 and following standard recommendations. 7 The integrated model was calculated as recently defined.
3 Risk-group stratification was also performed as originally defined, except for the EBMT score in which patients were divided into low (score 0-3), intermediate (score [4] [5] and high risk (score 6-7) according to percentiles 33, 66 and 100, respectively. All patients underwent laboratory studies, pulmonary function tests and echocardiography, which were performed in each center within day 30 and day 10 of hematopoietic cell transplantation (HCT). The individual predictive capacity of each model for NRM and overall survival (OS) was evaluated.
The primary end point of the study was NRM. Secondary end points were OS and relapse.
The incidences of NRM and relapse were calculated using cumulative incidence estimates, taking into account the competing risk model. 8 The probability of OS was estimated using Kaplan-Meier curves and compared using the Log-rank tests. 9 The c-statistic was calculated to estimate the predictive capacity of all models for NRM at 100 days, 2 years and 5 years as previously described. 10 The s.e. for the difference in c-statistic between the three models was estimated after bootstrapping and used to calculate a Z-score and a P-value for the difference.
All statistical analyses were performed using STATA version 13.1 and R 3.01 by R development Core Team (College Station, TX, USA).
Patients characteristics are summarized in Table 1 . In brief, median age at transplantation was 55 years (range 18-71). Most patients received allo-HCT from HLA identical sibling donors (n = 170, 73%) mainly for acute leukemia and myelodysplastic syndromes (n = 73, 32%). Reasons for proceeding with allo-RIC included age450 years (n = 151), previous HCT (n = 44) and comorbidities (n = 37). Median follow-up for survivors was 5.5 years (range 0.3-11).
The median HCT-CI, EBMT scores and the new integrated score were 3 (percentile 25-75: 2-5), 5 (percentile 25-75: 4-5) and 5 (percentile 25-75: 4-6), respectively. Distribution of patients according to each model is summarized in Table 2 .
Seventy-one patients experienced NRM for a cumulative incidence of 5-year NRM of 31% (95% CI 28-34). Distribution of the incidences of 5-years NRM according to the risk groups of each model appear in Table 2 . In brief, the probability of 5-year NRM progressively increased in the low-, intermediate-and highrisk groups according to all models ( Figure 1 ). The HRs for 5-year NRM according to the integrated score were low risk (HR 1.0, reference), intermediate risk (HR 1.2 (95% CI 0.8-1.6)) and high risk (HR 3.7 (95% CI 2.4-5.1)), global Po 0.001. The most common causes of NRM were GvHD and infection (35 patients died from GvHD with infection, 10 from infection without GvHD and 18 from GvHD without infection). Eight patients died of other non-GvHD and non-infection causes. Regarding the predictive capacity of the models of 5-year NRM, the c-statistic for the integrated score was 0.627 (95% CI 0.566-0.686) while for the HCT-CI and the EBMT score they were 0.573 (95% CI 0.523-0.623, P = 0.1) and 0.571 (95% CI 0.510-0.631, P = 0.2), respectively. Similar results were obtained for the prediction of NRM at 2 years (0.616 (integrated score), 0.565 (HCT-CI) and 0.566 (EBMT score)). Remarkably, for the prediction of early (100 days) NRM, the EBMT score showed the highest c-statistic value (0.636 (integrated score), 0.587 (HCT-CI) and 0.642 (EBMT score)).
The probability of OS for the whole cohort was 39% (95% CI 36-42). According to each model the OS was lower in the high-risk groups, although less clear differences were observed when compared with NRM regarding intermediate-and low-risk groups ( Table 2 ). The 5-year cumulative incidence of relapse was 33% (95% CI 30-36). None of the scores were able to predict relapse in this population (data not shown).
This study validates the recently published integrated predictive model for NRM of the ALWP of the EBMT in an independent, more heterogeneous (including several diseases) and longer followed population of allo-RIC patients.
The integrated score developed by Versluis et al. 3 was proposed as a new tool for prediction of NRM in allo-RIC patients. The main strengths of this study were a highly homogeneous population, a large number of patients and a relatively strong predictive capacity even after bootstrapping. In contrast, the data were obtained from a multicenter and international registry without an external validation and with a relatively short follow-up. Since the development of the HCT-CI, the accuracy in the assessment of comorbidities has been a concern. Sorror et al. 7 proposed guidelines on how to assess comorbidities in HCT patients. In these guidelines the authors advocated for a limited number of investigators in charge of comorbidity assessment and recommended that only trained personnel should be in charge of this task. Of note, none of these recommendations were met in the study by Versluis et al. 3 owing to its multicenter and multinational nature, but were strictly followed in our study.
Our group 11 and others 12 have recently explored the combination of the HCT-CI and the EBMT score on the prediction of NRM. In these studies, both models were combined unchanged in a new 6-category risk model, which improved the discrimination of patients for NRM compared with each of the individual models. Versluis et al.
3 combined both models but only by choosing the variables with a high HR for NRM in the multivariate analysis (41.2). Regarding comorbidities, this selection led to profound modifications according to the HCT-CI scores of two of the most frequent comorbid conditions in HCT recipients: hepatic and pulmonary impairment. These conditions received the maximal score (3) in the original HCT-CI, as they were associated with the two highest HR among all the 25 comorbidities explored in the training set. Other investigators have confirmed the profound impact of severe hepatic and pulmonary impairment and their high frequency among HCT recipients. 13, 14 In the integrated model, these two conditions were associated with modest HRs (o 1.4) and received the minimal score in the model (1) . This reclassification of risk points of each comorbid condition is debatable and should be explored in further studies.
By using the integrated model, we have identified a population (score ⩾ 7) with very high risk of NRM in line with the original results by Versluis et al. 3 If these results are confirmed, this new model could be used to identify patients with a potentially unacceptable risk for allo-HCT who should be carefully selected for the procedure.
Limitations of our study are derived from its retrospective nature and by a relatively high NRM in our series of heavily pretreated and highly comorbid population. Thus, we encourage other investigators to explore the predictive capacity of the integrated score in different allo-HCT populations, before implementation of this prognostic tool in clinical practice.
Our results show that the integrated score can be applied to other populations of allo-RIC patients (including several diseases and conditioning regimens) and is capable of predicting longterm NRM. Abbreviations: ATG = antithymocyte globulin; CNI = calcineurin inhibitor; HCT = hematopoietic stem cell transplantation; MDS = myelodysplastic syndrome; MMF = mycophenolate mophetil; MsM = HLA mismatch; MTX = methotrexate; n = number; NHL = non-Hodgkin lymphoma; VUD = volunteer unrelated donor. Abbreviations: CI = confidence interval; EBMT = European group for blood and marrow transplantation; HCT-CI = hematopoietic stem cell transplantation-comorbidity index; NRM = non-relapse mortality; N = number; OS = overall survival. Distribution of patients according to their score according to the 3 models. Outcome of each subgroup is given as cumulative incidence of NRM and probability of OS% (95% CI). The corrected c-statistic for NRM and OS for each of the three models appears as Harrell et al. (1984) c-statistic (95% CI). 
